Persistence of new TAA-T clones expanded in the product that were not present at baseline. (A) Using TCRVβ deep sequencing, new clones detected in the TAA-T product were identified and tracked in PB over time. (B) Longitudinal tracking of new clones expanded in product over time for patients receiving TAA-T alone. Multi-institutional Prospective Research of Expanded Multi-antigen Specifically Oriented Lymphocytes for the Treatment of VEry High Risk Hematopoietic Malignancies (RESOLVE) and TAA-T with nivolumab [TAA-T with nivolumab on Phase I Study Utilizing Tumor Associated Antigen Specific T cells (TAA-T) with PD1 Inhibitor Nivolumab for Relapsed/Refractory Lymphoma (SUSTAIN) trial]. (C) Tracking of clones enriched in TAA-T product and not present at baseline in patient 6.